Filings show Chinese gene sequencer BGI has paid out millions in legal fees battling Illumina over patents
Financial figures disclosed as supplement to IPO prospectus, in latest sign regulators are wary of waving through companies facing major overseas IP litigation
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.